See more : Scottie Resources Corp. (SCOT.V) Income Statement Analysis – Financial Results
Complete financial analysis of Pharmaniaga Berhad (7081.KL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmaniaga Berhad, a leading company in the industry within the sector.
- Central Petroleum Limited (CNPTF) Income Statement Analysis – Financial Results
- Vidhi Specialty Food Ingredients Limited (VIDHIING.BO) Income Statement Analysis – Financial Results
- Blue Ocean Acquisition Corp. (BOCNU) Income Statement Analysis – Financial Results
- CanBas Co., Ltd. (4575.T) Income Statement Analysis – Financial Results
- New Energy One Acquisition Corporation Plc (NEOA.L) Income Statement Analysis – Financial Results
Pharmaniaga Berhad (7081.KL)
Website: https://www.pharmaniaga.com
About Pharmaniaga Berhad
Pharmaniaga Berhad, an investment holding company, operates as an integrated pharmaceutical company in Malaysia, Indonesia, and internationally. The company operates through three segments: Logistics and Distribution, Manufacturing, and Indonesia. It is involved in manufacturing, distribution, trading, wholesaling, and marketing pharmaceutical and medical products; supply, trading, and installation of medical and hospital equipment; and trading and wholesaling of consumer products. The company also manufactures and sells generic drugs; over-the-counter medicines; conducts research and development of pharmaceutical products; and manufactures, distributes, trades in, and sells food supplements. In addition, it distributes and trades in diagnostic products; and operates community pharmacies under the RoyalePharma brand name. The company was founded in 1994 and is based in Shah Alam, Malaysia. Pharmaniaga Berhad is a subsidiary of Boustead Holdings Berhad.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.40B | 3.48B | 4.82B | 2.73B | 2.82B |
| Cost of Revenue | 3.10B | 3.69B | 4.19B | 2.43B | 2.48B |
| Gross Profit | 307.82M | -209.59M | 630.02M | 295.20M | 341.30M |
| Gross Profit Ratio | 9.04% | -6.02% | 13.08% | 10.83% | 12.10% |
| Research & Development | 0.00 | 10.23M | 5.21M | 7.95M | 11.85M |
| General & Administrative | 328.27M | 314.72M | 322.64M | 227.61M | 98.40M |
| Selling & Marketing | -26.39M | 0.00 | 0.00 | 0.00 | 131.10M |
| SG&A | 301.88M | 314.72M | 322.64M | 227.61M | 229.51M |
| Other Expenses | -20.45M | 2.69M | 165.00K | 530.00K | 0.00 |
| Operating Expenses | 307.82M | 314.39M | 322.30M | 227.27M | 494.30M |
| Cost & Expenses | 3.40B | 4.00B | 4.51B | 2.66B | 2.97B |
| Interest Income | 1.48M | 910.00K | 1.52M | 633.00K | 38.87M |
| Interest Expense | 61.84M | 40.04M | 33.32M | 33.70M | 40.26M |
| Depreciation & Amortization | -17.01M | 27.62M | 27.90M | 26.85M | 31.12M |
| EBITDA | -16.32M | -520.33M | 335.28M | 94.43M | 124.20M |
| EBITDA Ratio | -0.48% | -14.95% | 6.45% | 2.55% | 4.40% |
| Operating Income | 694.00K | -520.33M | 310.33M | 69.50M | 93.08M |
| Operating Income Ratio | 0.02% | -14.95% | 6.45% | 2.55% | 3.30% |
| Total Other Income/Expenses | -78.86M | -90.26M | -30.64M | -32.13M | -291.82M |
| Income Before Tax | -78.16M | -610.59M | 277.08M | 35.79M | -191.87M |
| Income Before Tax Ratio | -2.30% | -17.54% | 5.75% | 1.31% | -6.80% |
| Income Tax Expense | 581.00K | 17.07M | 104.87M | 9.52M | 42.42M |
| Net Income | -80.16M | -629.92M | 172.15M | 27.49M | -149.22M |
| Net Income Ratio | -2.35% | -18.10% | 3.58% | 1.01% | -5.29% |
| EPS | -0.06 | -0.48 | 0.13 | 0.02 | -0.11 |
| EPS Diluted | -0.06 | -0.48 | 0.13 | 0.02 | -0.11 |
| Weighted Avg Shares Out | 1.37B | 1.31B | 1.31B | 1.31B | 1.30B |
| Weighted Avg Shares Out (Dil) | 1.37B | 1.31B | 1.31B | 1.31B | 1.30B |
Source: https://incomestatements.info
Category: Stock Reports